Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences)

N/A

Report date: 2024/02/06 20:00:33

Base Information

Drug NameAnti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy

Mechanisms of ActionNatural killer cell replacementsAnti-BCMA

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIran

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesShahid Beheshti University Of Medical Sciences

China Registration ClassN/A

Develop Information

Active CompaniesShahid Beheshti University Of Medical Sciences

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A